Marco Hafner, study co-author and RAND Europe research advisor: * From this, population level intangible costs were estimated to be $92 billion across 12 countries in Europe, $10.7 billion in Canada and $127.1 billion per year in the United States for those of working-age range. It was found that people suffering from insomnia, including chronic insomnia disorder, would be willing to trade, on average, an estimated 14.0% of their per capita household income in order to recuperate the wellbeing loss associated with the condition. * The indirect economic costs reported by RAND are higher than costs reported in other literature. This equates to an estimated loss in annual GDP of approximately $170.7 billion for the 12 European countries analyzed, $19.6 billion for Canada and $207.5 billion for the United States. In terms of indirect costs, chronic insomnia disorder was associated with approximately 11 to 18 days of absenteeism, 39 to 45 days of presenteeism (defined as reduced productivity while at work), and 44 to 54 days of overall productivity loss annually. It's important that we acknowledge chronic insomnia as a legitimate medical condition and recognize the enormous burden it places on individuals and society as a whole.”Īccording to the recently published figures, the cost of chronic insomnia disorder is substantial. Despite sleep being a biological necessity to ensure optimal functioning throughout the day, 5 millions of people globally are not getting restorative sleep due to chronic insomnia disorder. Their findings are unique by revealing, for the first time, the indirect economic and ‘hidden’ wellbeing costs of chronic insomnia disorder. An example of our commitment to furthering this understanding is our sponsorship of the research published by RAND Europe. “Our scientists have over 20 years of experience in the field of sleep research, through the orexin system, and continue to work on better understanding of the science of sleep and chronic insomnia disorder. Jean-Paul Clozel, MD and Chief Executive Officer of Idorsia, commented: Conducting more research on the prevalence of CID and its societal and economic impacts.Addressing physician knowledge gaps and improving the identification and management of insomnia.Incorporating insomnia screening during routine clinical visits.1,2 The report also provided additional insights on chronic insomnia disorder.Īs part of the company’s ongoing commitment to advance research in insomnia, Idorsia supports RAND Europe’s recommendation and highlights the importance of: * 1 The intangible annual wellbeing losses range from $1.5 billion and $127.1 billion (for a total of $239.5 billion) in the countries of focus, which include France, Italy, Germany, Spain, the United Kingdom, the United States, and Canada. RAND Europe’s findings indicate the indirect economic costs associated with lost work productivity ranging between $1.8 billion and $207.5 billion (for a total of $417 billion) in gross domestic product (GDP) across the countries RAND analyzed. The new report focuses on both the indirect economic costs (i.e., non-healthcare related costs) and the “hidden” intangible costs (i.e., costs that are not directly observed through economic transactions but nonetheless have impacts on an individual’s health or well-being) associated with chronic insomnia disorder. Idorsia commissioned RAND Europe, an independent, not-for-profit policy research organization, to help fill some of the knowledge gaps associated with understanding the financial burden of chronic insomnia disorder and to deliver new peer-reviewed research into the impacts of insomnia. On World Sleep Day, Idorsia Ltd (SIX: IDIA) highlights the publication of a first-of-its-kind report by RAND Europe on the economic and societal impact of chronic insomnia disorder, † “ The Societal and Economic Burden of Insomnia in Adults: An International Study”.
0 Comments
Leave a Reply. |